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A B S T R A C T   
Ovarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiomyo-
sarcoma is the rarest subtype. Primary ovarian leiomyosarcoma has a very poor prognosis, with less than 20% of 
patients being alive at 5 years. Only a few cases have been published in the literature and there is very limited 
knowledge on the clinical behaviour and optimal management of these tumours. We have performed a retro-
spective analysis of a prospectively maintained database to identify all primary ovarian leiomyosarcoma diag-
nosed and treated at the Royal Marsden NHS Foundation Trust between 1998 and 2020. Sixteen patients were 
identified from our database and fifteen were eligible for the analysis. Twelve patients presented with localized 
disease and underwent initial surgery and three patients had metastatic disease at presentation. Recurrence-free 
survival post-surgery was 16 months. Eight patients received first-line chemotherapy and four patients received 
second-line chemotherapy. Two patients had indolent metastatic disease and benefited from local therapies only. 
The median overall survival in the metastatic setting in our cohort was 51 months, which is consistent with 
previously published cases. Primary ovarian leiomyosarcoma is an extremely rare malignancy with a poor 
prognosis. This study is the largest case series of primary ovarian leiomyosarcoma published to date, providing 
clinically important information regarding survival and metastatic rate as well as treatment outcomes in the 
metastatic setting.   
1. Background 
Primary ovarian leiomyosarcoma is a very rare form of malignancy 
which mainly occurs in women aged 45–60 years (Nazneen, et al., 2016; 
Pankaj et al., 2013; Goodalla et al., 2011; Arslan, 2011; Meng, 2016; 
Monk et al., 1993). Ovarian smooth muscle tumors represent 1% of all 
ovarian malignancies and ovarian leiomyosarcoma accounts approxi-
mately for 0.1% of all ovarian malignancies (Goodalla et al., 2011; 
Taşkin, 2007). Other sarcoma subtypes originating in the ovary include 
rhabdomyosarcomas, fibrosarcomas and stromal cell sarcomas 
(Goodalla et al., 2011). It is believed that these tumours arise from the 
malignant degeneration of smooth muscle present in the ovary, origi-
nating in the blood vessels, ovarian ligaments or the ovarian mesen-
chyme (Friedman and Mazur, 1991; Kurian et al., 2005). 
The initial symptoms are vague and can include lower abdominal 
pain, altered bowel and bladder habit, vaginal bleeding. Some patients 
present with bilateral hydronephrosis and incontinence (Pankaj et al., 
2013; Goodalla et al., 2011; Inoue et al., 2000). The tumour marker CA- 
125 is usually within normal values or mildly increased (Rasmussen, 
1997; Tanaka et al., 2018; Kaur, 2014). The International Federation of 
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Gynecology and Obstetrics (FIGO) classification and TNM Classification 
staging system are utilized to determine the appropriate management 
(Arslan, 2011; Tanaka et al., 2018; Furutake et al., 2017). The stage and 
the size of the tumour and the mitotic index impact the prognosis 
(Pankaj et al., 2013; Bouie, 2005), however, as in other gynecological 
sarcomas, primary ovarian leiomyosarcoma are not routinely graded. 
Histologically, primary ovarian leiomyosarcoma is diagnosed based 
on the presence of eosinophilic spindle-shaped cells with enlarged, 
variably pleomorphic nuclei, arranged in intersecting fascicles or sheets 
(Pankaj et al., 2013; Furutake et al., 2017; Kumar Vijaya et al., 2015; 
Bodner et al., 2003). The nuclei have blunted, or truncated ends and the 
cells have a dense cytoplasm. Other histological features are cellular 
atypia, presence of coagulative necrosis and increased, often atypical, 
mitoses (Friedman and Mazur, 1991). On immunohistochemistry, the 
tumours are diffusely strongly positive for desmin, smooth muscle actin 
(SMA), h-caldesmon, and sometimes bcl-2 (Pankaj et al., 2013; Tanaka 
et al., 2018; Furutake et al., 2017; Bouie, 2005; Kumar Vijaya et al., 
2015; Bodner et al., 2003; Lerwill et al., 2004). It also expresses estrogen 
and progesterone receptors (Bouie, 2005). 
Due to their rarity, there is very limited knowledge on the clinical 
behaviour and optimal management of these tumours. This study aims 
to provide a benchmark to guide clinical practice and future research. 
2. Ethics approval and consent to participate 
Institutional approval for use of the data was sought through the 
service evaluation that was approved (SE 934, date 24/05/2020) by the 
Royal Marsden Institutional Review Board. Because this was a 
Table 1 
Patients characteristics at diagnosis and outcomes of first line metastatic systemic therapy in ovarian leiomyosarcoma.  






(months) from surgery or 
adjuvant chemotherapy to 
disease recurrence or last 
follow-up 
1st line metastatic 
chemotherapy 
Best response Progression-free 
survival of first 






time to last 
follow-up if 
alive (months) 










12 Dead of 
disease 
25 
2 IA TAH + BSO No recurrence at 15 
months 
no systemic therapy 
received 
N/A  Lost to 
follow-up 
15 
3 IA TAH + BSO 14 doxorubicin x6 
cycles (at the local 
hospital – no 
information on 
outcome) 
Unknown  Dead of 
disease 
51 
4 IA TAH + BSO 31 gemcitabine- 





8 Dead of 
disease 
77 
5 IVB Palliative 
chemotherapy 






11 Dead of 
disease 
18 
6 IA RSO 16 no systemic therapy 
received 




7 IA TAH + BSO 15 gemcitabine- 
docetaxel x6 cycles 
Stable disease 7 Dead of 
disease 
56 
8 IA TAH + BSO 3 carboplatin- 
gemcitabine x5 
cycles 
Stable disease 4 Dead of 
disease 
22 
9 IA LSO No recurrence at 8 months no systemic therapy 
received 








11 doxorubicin N/A  Lost to 
follow-up 
12 
11 IVB No treatment due to 
poor performance 
status at diagnosis 
N/A no systemic therapy 
received 
N/A  Dead of 
disease 
2 
12 IA BSO 40 no systemic therapy 
received 




13 IA LSO No recurrence at 15 
months 
no systemic therapy 
received 




14 IIB TAH + BSO No recurrence at 13 
months 
no systemic therapy 
received 




15 IIIA2 TAH + BSO followed 





carboplatin x4 cycles 




TAH-BSO total abdominal hysterectomy and bilateral salpingo-oophorectomy; RSO right salpingo-oophorectomy; LSO left salpingo-oophorectomy. 
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retrospective study, written informed consent was not obtained from the 
subjects. At Royal Marsden Hospital, for retrospective clinical studies 
such as case reports and treatment effects, we confirm with patients the 
consent for comprehensive clinical studies. All participants in this study 
agree on its comprehensive research participation. 
3. Patients and methods 
We performed a retrospective search of the prospectively maintained 
Royal Marsden Hospital Sarcoma Database and identified all women 
diagnosed with primary ovarian leiomyosarcoma between January 
1998 and March 2020. The diagnosis of primary ovarian leiomyo-
sarcoma was confirmed by two experienced sarcoma specialist histo-
pathologists (KT, CF). Following surgery for localised disease (FIGO 
stages I-III), surveillance with computed tomography (CT) scan of the 
chest, abdomen and pelvis, was performed every 3 months for the first 2 
years, and then every 6 months up to 5 years and then annually for a 
total of 10 years. For patients treated with palliative chemotherapy, 
restaging was performed following every 2–3 cycles. Response evalua-
tion criteria in solid tumors 1.1 (RECIST 1.1) was used to assess response 
to therapy. Descriptive statistical analysis was performed using Statis-
tical Product and Service Solutions (SPSS) software. Survival was esti-
mated using Kaplan Meier curves. Data-cut for the analysis was 04/05/ 
2020. 
Our institution is a tertiary sarcoma center, with expertise in diag-
nosis and treatment of leiomyosarcomas. Herein we present our 
approach to management of ovarian leiomyosarcomas at diagnosis and 
at relapse. 
4. Results 
Patient demographics and tumour characteristics (Table 1) 
Sixteen women with a diagnosis of ovarian leiomyosarcoma were 
identified from our database, with one excluded as she was referred for a 
second opinion only. Of the 15 patients analyzed, the median age at 
diagnosis was 56 years (range 30–76). In the same period of time, 1958 
patients with leiomyosarcoma were diagnosed and treated in our insti-
tution, meaning that ovarian leiomyosarcoma represented 0.8% of all 
leiomyosarcoma tumours in our hospital. 
The ovarian masses were unilateral in 14 patients and bilateral in one 
patient (Patient 14). This patient had multifocal disease, with both 
ovaries involved and the uterus, but no other distant disease. Although 
there was relatively little atypia, there were enough features to warrant 
diagnosis of leiomyosarcoma in all 3 areas. It remains unclear as to 
whether the ovarian neoplasm represents metastases from the uterine 
neoplasm, or it represents synchronous malignant disease. Twelve pa-
tients (80%) had localized disease at diagnosis: FIGO stage IA in 9 pa-
tients, IIB in 2 patients and IIIA2 in one patient. Other three patients 
(20%) had metastatic disease at presentation, corresponding to stage 
IVB FIGO. Median tumour size at diagnosis, based on the largest diam-
eter, was 20 cm (range 6 – 26 cm). Only 3 patients in our cohort had a 
CA125 test performed at baseline and all values were within normal 
limits. 
4.1. Treatment of localized disease (FIGO stages I-IIIA) 
Surgery of the primary tumour was performed in all 12 patients 
presenting with localized disease as shown in Table 1. Only two patients 
(patients 10 and 15) received adjuvant chemotherapy with gemcitabine- 
docetaxel. One woman was treated with 5 cycles of adjuvant 
gemcitabine-docetaxel. Another woman withdrew consent after one 
cycle of adjuvant chemotherapy. The median relapse-free survival post- 
surgery in this group of localized disease was 16 months (95% CI 13.4 – 
18.5), with four patients remaining relapse-free at their last follow-up. 
4.2. Treatment of relapsed or metastatic disease (FIGO stage IVB) 
In our cohort of fifteen patients, three women had metastatic disease 
at initial diagnosis and eight other women developed metastatic relapse 
after initially being treated for localised cancer. The treatment of these 
eleven patients was determined by their disease burden. The most 
common sites of metastatic relapse were lungs, liver, bones and adrenal 
glands. One patient with advanced cancer at diagnosis did not receive 
any treatment due to poor performance status and died within 2 months 
of presentation (Patient 11). 
For two patients, palliative surgery was offered for low volume 
metastatic disease (Patients 6 and 12). Neither of these two patients 
have received any form of systemic therapy, and at the time of data-cut, 
they were still under surveillance with no macroscopic or low volume 
metastatic disease. 
First-line palliative chemotherapy was offered to eight patients with 
metastatic ovarian leiomyosarcoma. Doxorubicin alone or in combina-
tion with ifosfamide as first-line palliative chemotherapy was adminis-
tered in four out of eight patients. One woman (Patient 1) had 60% 
reduction in her disease, after receiving eight cycles of ifosfamide- 
doxorubicin, by RECIST 1.1. First-line gemcitabine plus docetaxel (six 
cycles) was given in two cases (Patients 4 and 7), with one partial 
response seen in Patient 4 (31% tumoral reduction by RECIST). 
Two patients, Patients 8 and 15, presented with two different biopsy- 
proven malignancies and received platinum-based regimens as first-line 
treatment, with the best response being stable disease. Patient 8 had a 
metastatic leiomyosarcoma of the ovary and a primary lung cancer, 
therefore, she received carboplatin-gemcitabine as first-line therapy. 
Patient 15 was treated with epirubicin-carboplatin as she had a 
concomitant head and neck squamous cell carcinoma alongside with her 
metastatic ovarian leiomyosarcoma. Her sarcoma remained stable after 
4 cycles of treatment received to date. Both these patients underwent 
resection of their second malignancy. It is possible that the high inci-
dence (2 out of 15 patients) of a second cancer in our cohort of ultra-rare 
cancers is due to the close radiological surveillance, although a familial 
predisposition could not be excluded. The median duration from the 
start of first-line palliative chemotherapy to progressive disease in all 
patients was 8 months (range 4–12). 
Second-line chemotherapy was given to 4 patients and included 
trabectedin, doxorubicin and pazopanib. The best response in this group 
was stable disease. The median duration from the start of second-line 
systemic therapy to progressive disease was 7.5 months (range 3–11). 
Third- and fourth-line systemic chemotherapy was given in 4 and 3 
patients, respectively. Regimens contained single agent ifosfamide, 
doxorubicin, trabectedin, dacarbazine or cyclophosphamide. The best 
radiological response for third- and fourth-line treatment was stable 
disease. 
Two women (Patients 4 and 5) have received radiation with pallia-
tive intent for symptomatic bone deposits. However, radiotherapy did 
not offer any local disease control for these two patients. Although most 
of these tumours expressed oestrogen or progesterone receptors, none of 
our patients received endocrine therapy for their cancer, mainly due to 
lack of published evidence or aggressive behavior necessitating treat-
ment with chemotherapy. 
4.3. Overall survival 
At the time of the analysis, seven patients have died of their disease. 
The median follow-up for our cohort was 18 months (range 2–98). The 
median survival rates were lower for the group of patients with meta-
static disease at presentation (FIGO stage IV) with a median overall 
survival of 18 months (95%CI 0.0 – 43.6), compared to the patients with 
localized disease at diagnosis (FIGO stages I-IIIA) where median overall 
survival was 56 months (95% CI 45.5–66.4), p = 0.004, hazard ratio for 
localized disease = 0.75 (95%CI 0.0–0.7) (Fig. 1). The estimated median 
overall survival for the 11 patients with metastatic disease in our study 
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was 51 months (95%CI 0.0–113.5). Subgroup analysis was not possible 
due to low number of patients. 
5. Discussion 
Primary ovarian leiomyosarcomas are a very rare sarcoma subtype, 
accounting for 0.8% of all leiomyosarcomas in our database and have 
limited treatment options in the metastatic setting. The prognosis of this 
cancer is poor, with reported 5-year survival rates less than 20% 
(Anderson et al., 1987; Dai, 2011). Furutake and colleagues have 
analyzed the survival data of 56 cases reported in the literature. The 
median overall survival was 48 months and 40% of these patients died 
within 24 months. The median survival was 14 months for stage III/IV 
FIGO and 18 months for stage II FIGO, compared to 63 months for stage I 
FIGO (Furutake et al., 2017). 
In our study, only 4 patients (26%) were recurrence-free at the time 
of data-cut analysis. However, as the surveillance period was short 
(8–15 months), it is possible that these patients would eventually relapse 
during their follow-up period. Other 2 patients with metastatic disease 
(13%) had indolent low volume disease, having been managed with a 
combination of active surveillance and local therapies. This suggests 
that some patients with metastatic primary ovarian leiomyosarcomas 
can have an indolent clinical course, and systemic therapy can be kept in 
reserve. This is supported by the fact that the median overall survival for 
all patients with metastatic disease in our series was 51 months. The 
overall survival within our cohort is consistent with previously pub-
lished cases (Pankaj et al., 2013; Goodalla et al., 2011; Arslan, 2011; 
Meng, 2016; Monk et al., 1993; Rasmussen, 1997; Nazneen, et al., 2016; 
Taşkin, 2007; Friedman and Mazur, 1991; Kurian et al., 2005; Inoue 
et al., 2000; Tanaka et al., 2018; Kaur, 2014; Furutake et al., 2017; 
Bouie, 2005; Kumar Vijaya et al., 2015; Bodner et al., 2003; Lerwill 
et al., 2004; Dixit, 1993; Brahima, 2017; Hensley et al., 2014). 
The recommended initial treatment for primary ovarian leiomyo-
sarcoma is complete resection (Dixit, 1993; Brahima, 2017). The Gy-
necological cancer InterGroup (GCIG) consensus review on uterine and 
ovarian leiomyosarcoma published in 2014 proposes total hysterectomy 
(TAH) and bilateral salpingo-oophorectomy (BSO) as initial surgical 
approach for ovarian leiomyosarcoma (Hensley et al., 2014). There is no 
proven benefit for adjuvant chemotherapy (Monk et al., 1993; Ras-
mussen, 1997; Taşkin, 2007; Tanaka et al., 2018; Furutake et al., 2017; 
Kumar Vijaya et al., 2015; Bodner et al., 2003). Surgery should be fol-
lowed by close surveillance for 10 years. The majority of patients will 
have local or distant relapse within the first two years. In the metastatic 
setting, our data, as well as retrospective case reports, suggest that 
prolonged tumour control can be obtained with chemotherapy, surgery, 
radiotherapy or radiofrequency ablation in some women with bone, 
liver or lung metastases (Rasmussen, 1997; Furutake et al., 2017). 
Palliative chemotherapy used for other soft tissue sarcomas has shown 
some benefit in metastatic leiomyosarcoma, most commonly used reg-
imens containing doxorubicin +/- ifosfamide, gemcitabine-docetaxel, 
trabectedin and platinum salts. 
The response rate and time to progression for patients treated with 
palliative systemic therapy are broadly similar to metastatic leiomyo-
sarcoma arising from other anatomic locations, despite the clear limi-
tations of such a comparison. Our study suggests that patients with 
metastatic primary ovarian leiomyosarcoma requiring systemic therapy 
should be treated with a similar algorithm to other leiomyosarcomas 
(Bathan et al., 2013). 
To our knowledge, this is the largest case series of primary ovarian 
leiomyosarcomas published to date, providing important information 
regarding the high metastatic rate of this tumour and treatment out-
comes in the metastatic setting. The limitations of this study include a 
low number of patients and the retrospective descriptive analyses. 
Further collaborative work with other specialist gynecological and sar-
coma centers is required to improve the outcome of patients with this 
very rare disease. 
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Fig. 1. Median overall survival for all patients with primary ovarian leiomyosarcoma. Metastatic corresponds to stage IV FIGO, whereas localized is stage I-III FIGO.  
E. Cojocaru et al.                                                                                                                                                                                                                               
Gynecologic Oncology Reports 36 (2021) 100737
5
Declaration of Competing Interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to influence 
the work reported in this paper. 
Acknowledgements 
We thank to Mr Omar Al-Muderis for his help in collecting the data. 
References 
Anderson, B., Turner, D.A., Benda, J., 1987. Ovarian sarcoma. Gynecol. Oncol. 26 (2), 
183–192. https://doi.org/10.1016/0090-8258(87)90272-1. PMID: 3643159.  
Arslan, O.S., et al., 2011. A rare tumor of the female genital tract: primary ovarian 
leiomyosarcoma. Arch. Gynecol. Obstet. 283 (Suppl 1), 83–85. https://doi.org/ 
10.1007/s00404-010-1735-3. PMID: 21061129.  
Bathan, A.J., Constantinidou, A., Pollack, S.M., Jones, R.L., 2013. Diagnosis, prognosis, 
and management of leiomyosarcoma: recognition of anatomic variants. Curr. Opin. 
Oncol. 25 (4). 
Bodner K, Bodner-Adler B, Czerwenka K, Hudelist G, Kimberger O, Leodolter S, 
Mayerhofer K: Bcl-2 expression in a primary leiomyosarcoma of the ovary: a case 
report. Wien Klin Wochenschr. 2003 Mar 31;115(5-6):191-5. PMID 12741081. 
Bouie, S.M., 2005. Cracchiolo B and Heller D (2005) Epithelioid leiomyosarcoma of the 
ovary. Gynecol. Oncol. 97 (2), 697–699. https://doi.org/10.1016/j. 
ygyno.2005.02.008. 
Brahima, et al., 2017. A rare ovarian tumour: primitive leiomyosarcoma of the ovary. 
J. Gynecol. Reprod. Med. 1 (2). 
Dai, Y., et al., 2011. Primary sarcoma of the ovary: clinicopathological characteristics, 
prognostic factors and evaluation of therapy. Chin. Med. J. (Engl) 124 (9), 
1316–1321. PMID: 21740740.  
Dixit, S., et al., 1993. Leiomyosarcoma of the ovary. J. Postgrad. Med. 39 (3), 151–153. 
PMID: 8051647.  
Friedman, H.D., Mazur, M., 1991. Primary ovarian leiomyosarcoma. An immuno- 
histochemical and ultrastructural study. Arch. Pathol. Lab Med. 115 (9), 941–945. 
PMID: 1929791.  
Furutake, Y., Fukagawa, T., Suga, Y., et al., 2017. Gemcitabine and docetaxel in a patient 
with primary ovarian leiomyosarcoma: a case report and review of literature. Int. 
Can. Conf. J. (7), 11–15. https://doi.org/10.1007/s13691-017-0309-7 (Accessed: 24 
Feb 2020).  
Goodalla, E.J., Madhuria, T., Manuela, S.B., 2011. The management dilemma of 
leiomyosarcoma of the ovary. World J. Oncol. 2 (5), 265–266. https://doi.org/ 
10.1007/s13691-017-0309-7 (Accessed: 25 Feb 2020).  
Hensley, M.L., Barrette, B.A., Baumann, K., Gaffney, D., Hamilton, A.L., Kim, J.W., 
Maenpaa, J.U., Pautier, P., Siddiqui, N.A., Westermann, A.M., Ray-Coquard, I., 2014. 
Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian 
leiomyosarcomas. Int. J. Gynecol. Can. 24 (9 Suppl 3), S61–S66. https://doi.org/ 
10.1097/IGC.0000000000000261. PMID: 25341583; PMCID: PMC4830912.  
Inoue, J., Gomibuchi, H., Minoura, S., 2000. A case of a primary ovarian 
leiomyosarcoma. J. Obstet. Gynaecol. Res. 26 (6), 401–407. https://doi.org/ 
10.1111/j.1447-0756.2000.tb01349.x. PMID: 11152324.  
Kaur, et al., 2014. Primary ovarian leiomyosarcoma: a case report with review. Int. J. 
Reprod. Contracept. Obstet. Gynecol. 3 (1), 258–260. 
Kumar Vijaya J, Khurana Anil, Kaur Paramjeet, Chuahan Ashok K, Singh Sunita (2015) A 
rare presentation of primary leiomyosarcoma of ovary in a young woman. ecancer, 
(9), p524. Available at: https://doi.org/10.1007/s13691-017-0309-7 (Accessed: 25 
Feb 2020). 
Kurian, R.R., Preethi, J., Remadevi, A.V., 2005. Leiomyosarcoma of ovary–a case report, 
Indian. J. Pathol. Microbiol. 48 (1), 19–20. 
Lerwill, M.F., Sung, R., Oliva, E., Prat, J., Young, R.H., 2004. Smooth muscle tumors of 
the ovary: a clinicopathologic study of 54 cases emphasizing prognostic criteria, 
histologic variants, and differential diagnosis. Am. J. Surg. Pathol. 28 (11), 
1436–1451. https://doi.org/10.1097/01.pas.0000141393.99300.d0. PMID: 
15489647.  
Meng, H.E., et al., 2016. Synchronous leiomyosarcoma and fibroma in a single ovary: a 
case report and review of the literature. Oncol. Lett. 11, 2510–2514. PMID 
27073508.  
Monk, B.J., Nieberg, R., Berek, J.S., 1993. Primary leiomyosarcoma of the ovary in a 
perimenarchal female. Gynecol. Oncol. 48, 389–393. https://doi.org/10.1006/ 
gyno.1993.1067. PMID: 8462904.  
Nazneen et al, Prolonged survival of a young female with high-grade pleomorphic 
leiomyosarcoma of ovary without recurrence, The journal of Obstetrics and 
Gynaecology of India (November – December 2016), 66 (S2): S639-S641. 
Pankaj, S., Choudhary, V., Singh, R.J., Harsvardhan, R., 2013. High grade pleomorphic 
leiomyosarcoma of ovary in young female: a case report. World J. Surg. Res. 2, 7–11. 
Rasmussen, C.C., et al., 1997. Stage IIIC ovarian leiomyosarcoma in a premenopausal 
woman with multiple recurrences: prolonged survival with surgical therapy. 
Gynecol. Oncol. 66 (3), 519–525. https://doi.org/10.1006/gyno.1997.4824. PMID: 
9299270.  
Tanaka, A., Miyoshi, A., Kanao, S., Takeda, M., Mimura, M., Nagamatsu, M., Yokoi, T., 
2018. Case Report of a Primary Ovarian Leiomyosarcoma Diagnosed by H- 
Caldesmon Staining. Journal of Clinical Gynecology and Obstetrics, North America, 
7(1), p26-29. Available at: https://doi.org/10.14740/jcgo477w (Accessed: 26 Feb 
2020). 
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